AE Wealth Management LLC Has $2.15 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

AE Wealth Management LLC lessened its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 25.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 128,134 shares of the company’s stock after selling 44,852 shares during the period. AE Wealth Management LLC’s holdings in Teva Pharmaceutical Industries were worth $2,148,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. New Age Alpha Advisors LLC bought a new stake in Teva Pharmaceutical Industries during the first quarter worth $43,000. Sound Income Strategies LLC raised its stake in Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after acquiring an additional 2,824 shares in the last quarter. Banque Cantonale Vaudoise bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $74,000. Brooklyn Investment Group grew its holdings in shares of Teva Pharmaceutical Industries by 403.4% during the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after purchasing an additional 4,014 shares during the last quarter. Finally, CWM LLC grew its stake in shares of Teva Pharmaceutical Industries by 18.1% in the second quarter. CWM LLC now owns 4,995 shares of the company’s stock worth $84,000 after purchasing an additional 767 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the sale, the director owned 495,000 shares in the company, valued at $11,934,450. This represents a 28.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.49% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on TEVA shares. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. UBS Group raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $25.86.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $25.11 on Wednesday. The firm has a fifty day simple moving average of $19.98 and a two-hundred day simple moving average of $18.03. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $25.35. The company has a market capitalization of $28.80 billion, a PE ratio of -156.94, a P/E/G ratio of 1.11 and a beta of 0.70. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.10. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business had revenue of $4.48 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter last year, the business posted $0.69 EPS. The business’s revenue was up 3.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. Research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.